Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naive Chronic Hepatitis B Patients at 48 Weeks
Gut and Liver
;
: 478-485, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-56818
ABSTRACT
BACKGROUND/AIMS:
To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV.METHODS:
In total, 168 treatment-naive CHB patients were enrolled, including 117 hepatitis B e antigen (HBeAg)-positive patients and 51 HBeAg-negative patients who met the inclusion criteria. All patients were treated with ADV 10 mg per day for 48 weeks. Multiple logistic regression analyses were used to investigate baseline factors, and responses at weeks 12 and 24 were analyzed as predictive values.RESULTS:
Multiple regression analyses showed that baseline HBeAg status and HBV DNA levels significantly affected the virological response (VR) (p or =10(3) copies/mL at week 24 is observed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
DNA
/
Adenina
/
Índice de Massa Corporal
/
Modelos Logísticos
/
Hepatite B Crônica
/
Organofosfonatos
/
Hepatite B
/
Antígenos E da Hepatite B
/
Hepatite Crônica
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Gut and Liver
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS